Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) EBIT Margin: 2014-2025

Historic EBIT Margin for CytomX Therapeutics (CTMX) over the last 11 years, with Sep 2025 value amounting to -264.43%.

  • CytomX Therapeutics' EBIT Margin fell 27673.00% to -264.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.46%, marking a year-over-year increase of 1516.00%. This contributed to the annual value of 18.10% for FY2024, which is 2451.00% up from last year.
  • CytomX Therapeutics' EBIT Margin amounted to -264.43% in Q3 2025, which was down 3,736.51% from -6.89% recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' EBIT Margin registered a high of 46.41% during Q4 2024, and its lowest value of -354.67% during Q1 2022.
  • For the 3-year period, CytomX Therapeutics' EBIT Margin averaged around -18.34%, with its median value being -2.28% (2023).
  • Per our database at Business Quant, CytomX Therapeutics' EBIT Margin skyrocketed by 33,061bps in 2023 and then tumbled by 27,673bps in 2025.
  • Over the past 5 years, CytomX Therapeutics' EBIT Margin (Quarterly) stood at -313.54% in 2021, then spiked by 26,629bps to -47.25% in 2022, then soared by 4,497bps to -2.28% in 2023, then skyrocketed by 4,869bps to 46.41% in 2024, then crashed by 27,673bps to -264.43% in 2025.
  • Its EBIT Margin was -264.43% in Q3 2025, compared to -6.89% in Q2 2025 and 44.43% in Q1 2025.